He Rong-Quan, Qin Mei-Jiao, Lin Peng, Luo Yi-Huan, Ma Jie, Yang Hong, Hu Xiao-Hua, Chen Gang
Department of Medical Oncology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Department of Medical Ultrasonography, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Cell Physiol Biochem. 2018;46(2):591-608. doi: 10.1159/000488627. Epub 2018 Mar 28.
BACKGROUND/AIMS: Whether the level of long noncoding RNA plasmacytoma variant translocation 1 gene (lncRNA PVT1) expression influences the clinical development and outcome of human cancers has not been thoroughly elucidated to date. Inconsistencies still exist regarding the associations between PVT1 and the clinicopathological features, including patient survival data. Additionally, the regulatory mechanism of PVT1 among human cancers remains unclear.
we conducted a comprehensive inquiry to verify the implication of PVT1 expression in cancer patients by conducting a meta-analysis of 19 selected studies and The Cancer Genome Atlas (TCGA) database to examine the relationship between PVT1 expression and both the prognosis and clinicopathological features of cancer patients using STATA 12.0. In addition, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the potential mRNA target genes of PVT1 gathered from TANRIC and Multi Experiment Matrix (MEM) were performed.
The level of PVT1 expression in tumor tissues was higher than in paired non-cancer tissues and was significantly associated with a poorer prognosis in cancer patients. Additionally, overexpression of PVT1 was significantly correlated with histological differentiation, tumor (T) classification, lymph node (N) classification and TNM stages. Furthermore, a total of 462 validated target genes were identified, and the GO and KEGG analyses demonstrated that the validated targets of PVT1 were significantly enriched in several pathways, including the GnRH signaling pathway, the Cytokine-cytokine receptor interaction pathway, the Inflammatory mediator regulation of TRP channels pathway, and the Neuroactive ligand-receptor interaction pathway.
PVT1 may serve as a potential biomarker associated with the progression and prognosis of human cancers.
背景/目的：长链非编码RNA浆细胞瘤变异易位1基因（lncRNA PVT1）的表达水平是否会影响人类癌症的临床发展及预后，迄今为止尚未得到充分阐明。关于PVT1与包括患者生存数据在内的临床病理特征之间的关联，仍存在不一致之处。此外，PVT1在人类癌症中的调控机制仍不清楚。
我们进行了一项全面的调查，通过对19项选定研究和癌症基因组图谱（TCGA）数据库进行荟萃分析，以验证PVT1表达在癌症患者中的意义，并使用STATA 12.0研究PVT1表达与癌症患者预后及临床病理特征之间的关系。此外，对从TANRIC和多实验矩阵（MEM）收集的PVT1潜在mRNA靶基因进行了基因本体论（GO）和京都基因与基因组百科全书（KEGG）通路富集分析。
肿瘤组织中PVT1的表达水平高于配对的非癌组织，且与癌症患者较差的预后显著相关。此外，PVT1的过表达与组织学分化、肿瘤（T）分级、淋巴结（N）分级和TNM分期显著相关。此外，共鉴定出462个经过验证的靶基因，GO和KEGG分析表明，PVT1的验证靶点在包括促性腺激素释放激素信号通路、细胞因子-细胞因子受体相互作用通路、TRP通道的炎症介质调节通路和神经活性配体-受体相互作用通路等多种通路中显著富集。
PVT1可能作为一种与人类癌症进展和预后相关的潜在生物标志物。
